Hard season for Chelsea, says Conte
They struggled without the Spanish striker against Palace, with Michy Batshuayi failing to impress. Today Moses's injury is another big loss for us. "We have to hope Victor's not too bad".

Clues to Identify Price Direction: Comcast Corporation (CMCSA)
Global Endowment Mgmt L P reported 12,240 shares or 0.06% of all its holdings. (NASDAQ:SPSC) to report earnings on October, 26. With 1.00 million avg volume, 4 days are for Avnet Incorporated (NYSE:AVT)'s short sellers to cover AVT's short positions.

Allegations send Crown shares plummeting
The explosive allegations of misconduct by whistleblower staff could raise questions of Crown's fitness to hold a casino licence. Speaking later to reporters, Wilkie described some of the allegations unrelated to poker machines as "quite chilling".

Happy Diwali 2017: Images, Wishes and Greetings
AsianDate looks forward to celebrate the key Indian festival of lights, Diwali on October 19 with members from all over the globe. Family members invite their friends, relatives and nearest ones to their homes and serve the freshly cooked meal to them.

Sensex Down 60 Points Ahead Of Long Weekend; Nifty At 10205
MSCI's broadest index of Asia-Pacific shares outside Japan was up 0.1 percent having gained 10 of the past 12 sessions. At 10:44 AM, the Sensex was down by 107.89 points to reach 32,501.07 while Nifty fell 40.00 points to touch 10,193.95.

Nokia 9 Concept Render Video Shows Off a Bezel-less Display
The current Nokia smartphone lineup has a pretty significant void between the lower mid-range Nokia 6 and the flagship Nokia 8 . As far as the design of the Nokia 7 is concerned, it may feature a metallic frame along with glass or polycarbonate chassis.

Joey Barton predicts where Chelsea will finish this season
Victor Moses was the latest casualty at the weekend, joining N'Golo Kante , Alvaro Morata and Danny Drinkwater on the sidelines. ANTONIO CONTE , Chelsea's Italian manager, on injuries decimating what he perceives as an already under-strength squad.

A US judge has invalidated patents on Allergan PLC's dry-eye medicine Restasis (cyclosporine ophthalmic emulsion) on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5%. In the 135 page opinion, Judge Bryson held as invalid and obvious all 13 asserted claims (representative of 113 claims) in 4 Orange Book Listed patents covering the drug Restasis®.

Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drug-makers Mylan NV, Teva Pharmaceutical Industries Ltd., and Akorn, Inc.

Allergan said it planned to appeal the decision. For purposes of the judgment, the Court allowed the Indian Tribe to join as co-plaintiff, without finding the patent assignment to them to be valid.

Still, the decision was a setback for the company, whose stock dipped more than 5 percent on the news.

The case was regarding Restasis, a blockbuster eye drug whose patents Allergan had in September given to the Saint Regis Mohawk Tribe. The tribe did not claim sovereign immunity in that case.

Bryson also criticized Allergan's recent deal to transfer the patents to a Native American tribe, which the company has said was an effort to protect them from administrative review by the U.S. Patent and Trademark Office, not challenges in federal court.

"While Allergan has pointed to evidence of objective considerations such as commercial success and long-felt unmet need, the force of that evidence is considerably blunted by the fact that, based on protection from a succession of patents, Allergan was able to foreclose competition in cyclosporin/glyceride emulsion formulations from the early 1990s until 2014", the decision said. But his decision on Monday rendered Allergan's move largely meaningless, since he invalidated the Restasis patents himself instead of waiting for the patent office to rule.

Wipro Shares Gain Over 3% After September Quarter ResultsDuring the quarter, IT services revenues in dollar terms showed a growth of 2.1 per cent over the preceding quarter. The company has also crossed the milestone of $2 billion revenue in IT Services in the United States dollars terms.

Bryson said "sovereign immunity should not be treated as a monetizable commodity that can be purchased by private entities as part of a scheme to evade their legal responsibilities".

But Monday's decision wasn't made by that patent review board.

"The Court has serious concerns about the legitimacy of the tactic that Allergan and the Tribe have employed", Bryson said.

The tribe had countered that it was within its rights and that further deals could serve as an added source of revenue for its community of more than 15,000 people in a rural, economically depressed region near the Canadian border.

It was unclear exactly when a generic version of Restasis might be available to consumers.

David Maris, an analyst for Wells Fargo, estimated in a note to investors Monday that a generic alternative would likely not enter the market until 2019.